| Literature DB >> 33569186 |
Qixun Wang1,2, Jinghang Li1, Xiaowei Wang1.
Abstract
BACKGROUND: The neutrophil-lymphocyte ratio (NLR) has been recognized as a useful marker of poor prognosis in non-cardiac surgery patients. But, the prognostic function of NLR in cardiovascular surgery patients still largely unknown. The aim of this study was to explore the relationship between postoperative NLR and mortality in cardiac surgery patients.Entities:
Keywords: Cardiac surgery; complications; mortality; neutrophil-lymphocyte ratio (NLR)
Year: 2021 PMID: 33569186 PMCID: PMC7867821 DOI: 10.21037/jtd-20-2593
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Figure 1The procedure of data selection and exclusion. MIMIC-III, Medical Information Mart for Intensive Care III.
Figure 2The ROC curves of NLR and 1-year postoperative mortality. ROC, receiver operating characteristic; NLR, neutrophil-lymphocyte ratio.
Baseline and clinical characteristics of the study population
| Variables | NLR <7.28 (N=1,733) | NLR ≥7.28 (N=974) | P value |
|---|---|---|---|
| NLR | 3.9±1.6 | 17.1±15.3 | <0.001 |
| Cardiac surgery | <0.001 | ||
| CABG | 1,185 (72.3) | 455 (27.7) | |
| Valvular surgery | 317 (50.2) | 315 (49.8) | |
| CABG + valvular surgery | 231 (53.1) | 204 (46.9) | |
| Age, years | 66.5±12.3 | 68.6±12.8 | <0.001 |
| Gender, male | 1,221 (70.5) | 643(66.0) | 0.017 |
| BMI, kg/m2 | 28.9±6.0 | 28.2±6.1 | <0.001 |
| Comorbidities | |||
| Hypertension | 1,282 (74.0) | 619 (63.6) | <0.001 |
| Congestive heart failure | 551 (31.8) | 487 (50.0) | <0.001 |
| Diabetes | 625 (36.1) | 294 (30.2) | 0.002 |
| Chronic pulmonary diseases | 256 (14.8) | 154 (15.8) | 0.468 |
| Renal failure | 170 (9.8) | 157 (16.1) | <0.001 |
| Laboratory tests | |||
| WBC, 109/L | 14.4±6.6 | 16.3±7.2 | <0.001 |
| Platelet, 109/L | 210.9±73.0 | 227.1±97.0 | 0.001 |
| Hemoglobin, g/dL | 12.6±1.6 | 12.1±1.7 | <0.001 |
| Lactate, mmol/L | 3.0±1.6 | 3.8±2.9 | <0.001 |
| Creatinine, mg/dL | 1.2±1.0 | 1.5±1.4 | <0.001 |
| BUN, mg/dL | 19.7±10.9 | 25.8±16.3 | <0.001 |
| APTT, s | 49.9±27.2 | 56.9±33.5 | <0.001 |
| PT, s | 16.0±2.8 | 17.1±6.6 | <0.001 |
| Anion gap, mmol/L | 12.8±2.9 | 14.34±3.7 | <0.001 |
| Bicarbonate, mmol/L | 25.1±2.7 | 25±3.2 | <0.001 |
| Chloride, mmol/L | 109.3±4.3 | 108.2±5.3 | <0.001 |
| Sodium, mmol/L | 139.4±2.8 | 139.6±3.7 | 0.171 |
| Potassium, mmol/L | 5.4±0.8 | 5.4±0.9 | 0.104 |
| Glucose, mg/dL | 131.9±23.3 | 136.7±29.5 | <0.001 |
| Vital signs | |||
| Heart rate, beats/min | 84.7±10.4 | 86.3±11.7 | 0.003 |
| MAP, mmHg | 75.4±7.0 | 74.0±7.7 | <0.001 |
| Respiratory rate, beats/min | 17.2±2.8 | 17.9±3.6 | <0.001 |
| Temperature, °C | 36.9±0.5 | 36.9±0.6 | 0.945 |
| SPO2, % | 97.9±1.3 | 97.7±1.9 | 0.026 |
| SOFA score | 4.8±2.6 | 5.6±3.1 | <0.001 |
Values are expressed as mean ± SD or n (%). NLR, neutrophil-lymphocyte ratio; CABG, coronary artery bypass graft; BMI, body mass index; WBC, white blood cell; APTT, activated partial thromboplastin time; PT, prothrombin time; MAP, mean arterial pressure; SOFA, sequential organ failure assessment; SD, standard deviation.
Clinical outcomes between study cohorts
| Outcomes | NLR <7.28 (N=1,733) | NLR ≥7.28 (N=974) | P value |
|---|---|---|---|
| First outcome | |||
| 30-day mortality | 28 (1.6) | 57 (5.9) | <0.001 |
| 90-day mortality | 43 (2.5) | 108 (11.1) | <0.001 |
| One-year mortality | 83 (4.8) | 144 (14.8) | <0.001 |
| Second outcome | |||
| CRRT | 22 (1.3) | 84 (8.6) | <0.001 |
| Length of ICU stay, days | 3.6±4.1 | 9.5±13.2 | <0.001 |
| Length of hospital stay, days | 10.7±6.4 | 18.3±14.4 | <0.001 |
| Length of ventilation time, hours | 24.9±65.3 | 121.9±258.3 | <0.001 |
| ICU stay ≥3 days | 660 (39.1) | 643 (67.4) | <0.001 |
| Hospital stay ≥14 days | 348 (20.2) | 493 (51.1) | <0.001 |
| Ventilation time ≥48 hours | 157 (9.5) | 325 (35.6) | <0.001 |
Values are expressed as mean ± SD or n (%). NLR, neutrophil-lymphocyte ratio; CRRT, continuous renal replacement therapy; SD, standard deviation.
The cox regression model of NLR and mortality
| Outcomes | Non-adjusted model | Adjusted model | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| 30-day mortality | 3.70 (2.35, 5.81) | <0.001 | 2.18 (1.15, 4.14) | 0.017 | |
| 90-day mortality | 4.66 (3.27, 6.64) | <0.001 | 2.21 (1.33, 3.69) | 0.002 | |
| One-year mortality | 3.29 (2.51, 4.32) | <0.001 | 1.58 (1.05, 2.38) | 0.030 | |
Adjusted for the confounders: cardiac surgery type, age, gender, BMI, comorbidities (hypertension, congestive heart failure, diabetes, chronic pulmonary diseases, renal failure), laboratory tests (WBC, platelet, hemoglobin, lactate, creatinine, BUN, APTT, PT, anion gap, bicarbonate, chloride, glucose), vital signs (heart rate, MAP, respiratory rate, temperature, SPO2), SOFA score. NLR, neutrophil-lymphocyte ratio; HR, hazard ratio; CI, confidence interval; BMI, body mass index; WBC, white blood cell; BUN, blood urea nitrogen; APTT, activated partial thromboplastin time; PT, prothrombin time; MAP, mean arterial pressure; SOFA, sequential organ failure.
Figure 3The survival curves of cox function analysis and Kaplan-Meier survival analysis. (A) The 1-year survival curves of cox function analysis between two NLR groups; (B) the 1-year Kaplan-Meier survival curve of two groups. Group 0 present NLR <7.28, group 1 present NLR ≥7.28. NLR, neutrophil-lymphocyte ratio.
The logistics regression of NLR and other clinical outcomes
| Outcomes | Non-adjusted model | Adjusted model | |||
|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | ||
| 30-day mortality | 3.79 (2.40, 5.99) | <0.001 | 2.25 (1.14, 4.43) | 0.019 | |
| 90-day mortality | 4.90 (3.41, 7.04) | <0.001 | 2.49 (1.44, 4.28) | 0.001 | |
| CRRT | 7.34 (4.56, 11.82) | <0.001 | 3.01 (1.41, 6.42) | 0.004 | |
| ICU stay ≥3 days | 3.22 (2.72, 3.80) | <0.001 | 2.55 (1.61, 4.03) | <0.001 | |
| Hospital stay ≥14 days | 4.13 (3.48, 4.91) | <0.001 | 3.32 (2.45, 4.49) | <0.001 | |
| Ventilation time ≥48 hours | 5.24 (4.24, 6.49) | <0.001 | 4.16 (2.93, 5.89) | <0.001 | |
Adjusted for the confounders: cardiac surgery type, age, gender, BMI, comorbidities (hypertension, congestive heart failure, diabetes, chronic pulmonary diseases, renal failure), laboratory tests (WBC, platelet, hemoglobin, lactate, creatinine, BUN, APTT, PT, anion gap, bicarbonate, chloride, glucose), vital signs (heart rate, MAP, respiratory rate, temperature, SPO2), SOFA score. NLR, neutrophil-lymphocyte ratio; OR, odds ratio; CI, confidence interval; CRRT, continuous renal replacement therapy; BMI, body mass index; WBC, white blood cell; BUN, blood urea nitrogen; APTT, activated partial thromboplastin time; PT, prothrombin time; MAP, mean arterial pressure; SOFA, sequential organ failure.